Previous 10 | Next 10 |
Image source: The Motley Fool. ClearPoint Neuro, Inc. (NASDAQ: CLPT) Q2 2022 Earnings Call Aug 09, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: ClearPoint Neuro, Inc. (CLPT) Q2 2022 Earnings Call Transcript
ClearPoint Neuro, Inc. (CLPT) Q2 2022 Earnings Conference Call August 09, 2022 04:30 PM ET Company Participants Joe Burnett - Chief Executive Officer Danilo D’Alessandro - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake S...
ClearPoint Neuro ( NASDAQ: CLPT ) on Tuesday said it had received a U.S. FDA medical device clearance for its Maestro Brain Model. The brain model was given a so-called 510(k) clearance. CLPT said the Maestro model was intended to label, visualize and shape the bra...
ClearPoint Neuro press release ( NASDAQ: CLPT ): Q2 GAAP EPS of -$0.18 in-line. Revenue of $5.2M (+52.5% Y/Y) beats by $0.12M . The Company reaffirms its full year 2022 revenue outlook of between $21.0 and $22.0 million. For further details see: ClearPoin...
SOLANA BEACH, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced financial results for its second quarter ended June 30...
SOLANA BEACH, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced it has received 510(k) clearance for its ClearPoint Maestro...
SOLANA BEACH, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that Mary McNamara-Cullinane has joined the Company as Vice...
SOLANA BEACH, Calif., July 26, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that it will release financial results for its 2022 second ...
CLPT has been growing revenues steadily and has a large addressable market. It also has a very strong moat due to the nature of the FDA approval process. While current valuation isn't compelling, long term this should be a winner. Introduction Today I'd like to begin my ...
SOLANA BEACH, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, congratulates partner PTC Therapeutics for being granted marketing authoriz...
News, Short Squeeze, Breakout and More Instantly...
ClearPoint Neuro, Inc. Company Name:
CLPT Stock Symbol:
NASDAQ Market:
SOLANA BEACH, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced it has initiated the Limited Market Release fo...
SOLANA BEACH, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene t...
SOLANA BEACH, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its...